NextCure, Inc.
(NASDAQ : NXTC)

( )
NXTC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.43%67.830.0%$2120.05m
NVAXNovavax, Inc. 7.12%133.2896.5%$1132.56m
SRNESorrento Therapeutics, Inc. 4.84%13.012.8%$802.96m
GILDGilead Sciences, Inc. -0.96%68.181.0%$567.95m
AMGNAmgen, Inc. -0.52%240.461.3%$471.70m
REGNRegeneron Pharmaceuticals, Inc. -0.24%610.892.7%$384.77m
VRTXVertex Pharmaceuticals, Inc. -1.37%267.151.9%$353.16m
BNTXBioNTech SE 2.74%71.000.0%$353.03m
ILMNIllumina, Inc. 2.73%353.533.5%$351.76m
BIIBBiogen, Inc. -1.60%288.541.6%$350.10m
ATNMActinium Pharmaceuticals, Inc. 3.77%9.9113.3%$236.61m
VXRTVaxart, Inc. -1.20%9.090.0%$212.23m
EBSEmergent BioSolutions, Inc. 4.17%134.976.4%$199.46m
MCRBSeres Therapeutics, Inc. 21.31%28.583.6%$186.90m
ALXNAlexion Pharmaceuticals, Inc. -0.87%101.892.0%$163.07m

Company Profile

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.